Buncharoen Wararut, Saenphet Kanokporn, Saenphet Supap, Thitaram Chatchote
Department of Biology, Faculty of Science, Chiang Mai University, Chiang Mai 50200, Thailand.
Department of Companion Animal and Wildlife Clinical Small Animal Clinic, Faculty of Veterinary Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.
J Ethnopharmacol. 2016 Dec 24;194:483-494. doi: 10.1016/j.jep.2016.10.036. Epub 2016 Oct 11.
Traditional medicine has used Uvaria rufa Blume as an ethnomedicinal plant for treating fever, skin allergies, intestinal ulcers and prostate disorders including BPH. However, no scientific evidence supports the traditional use.
This study aimed to evaluate the therapeutic potential of U. rufa on BPH using in vitro and in vivo models.
In vitro studies screened the efficacy of a 5α-reductase (5αR) inhibition and antioxidant activity of petroleum ether, ethyl acetate, ethanol and aqueous extracts from the stem of U. rufa. Phytochemical screening was performed to determine the active compound using high-performance liquid chromatography (HPLC). Ethyl acetate extract (UR-EtOAc) of U. rufa was used to evaluate the therapeutic efficacy in vivo models. BPH was induced by subcutaneous injection of testosterone propionate (3mg/kg) to male rats for 30 days. After 30 days of oral administration of UR-EtOAc at doses of 10 and 20mg/kg and finasteride at a dose of 1mg/kg, the prostate weight, prostate index (PI), testosterone and androgen receptor (AR) levels, and histopathological alteration of prostate gland were determined. Also, oxidative status and toxicity indices were assessed.
UR-EtOAc exhibited the highest potency of inhibition of 5αR and possessed potent antioxidants rich in phenolics and flavonoids contents. The active compound analyzed by HPLC was β-sitosterol. In vivo results show a significant reduction in prostate weight, PI, and AR in all treated groups when compared to the BPH model group (P<0.001). Also, the UR-EtOAc and finasteride treated groups had increased prostatic and serum testosterone levels when compared to the BPH model group. A histopathological investigation of the prostate glands supported the above results. UR-EtOAc elevated the antioxidant enzymes and reduced the malondialdehyde level in BPH-induced rats. Moreover, treatment of UR-EtOAc at all doses had no toxic effects on the vital organs and serum biochemical indices.
UR-EtOAc from the stem of Uvaria rufa Blume appears to have the potential as a phytotherapeutic agent in the management of BPH, which provides the scientific evidence for traditional use.
传统医学将红野独活用作民族药用植物，用于治疗发热、皮肤过敏、肠道溃疡和前列腺疾病，包括良性前列腺增生（BPH）。然而，尚无科学证据支持其传统用途。
本研究旨在使用体外和体内模型评估红野独活对BPH的治疗潜力。
体外研究筛选了红野独活茎部石油醚、乙酸乙酯、乙醇和水提取物对5α-还原酶（5αR）的抑制作用及抗氧化活性。采用高效液相色谱（HPLC）进行植物化学筛选以确定活性化合物。红野独活的乙酸乙酯提取物（UR-EtOAc）用于评估体内模型的治疗效果。通过给雄性大鼠皮下注射丙酸睾酮（3mg/kg）30天诱导BPH。在以10mg/kg和20mg/kg的剂量口服UR-EtOAc以及以1mg/kg的剂量口服非那雄胺30天后，测定前列腺重量、前列腺指数（PI）、睾酮和雄激素受体（AR）水平以及前列腺组织病理学改变。此外，评估氧化状态和毒性指标。
UR-EtOAc表现出最高的5αR抑制效力，并具有富含酚类和黄酮类成分的强效抗氧化剂。通过HPLC分析的活性化合物为β-谷甾醇。体内结果显示，与BPH模型组相比，所有治疗组前列腺重量、PI和AR均显著降低（P<0.001）。此外，与BPH模型组相比，UR-EtOAc和非那雄胺治疗组前列腺和血清睾酮水平升高。前列腺组织病理学检查支持上述结果。UR-EtOAc提高了BPH诱导大鼠的抗氧化酶活性并降低了丙二醛水平。此外，所有剂量的UR-EtOAc治疗对重要器官和血清生化指标均无毒性作用。
红野独活茎部的UR-EtOAc似乎具有作为植物治疗剂治疗BPH的潜力，这为其传统用途提供了科学证据。
